ライフサイエンスコーパス: outcome

1 weeks post-treatment (SVR12) was the primary outcome.

2 711 women had available data for the primary outcome.

3 erse events and large variations in survival outcome.

4 ing the opportunity for an improved clinical outcome.

5 lens, ciliary body) correlated with clinical outcome.

6 ppearing to carry a heightened risk for each outcome.

7 osine with GM-CSF do not improve therapeutic outcome.

8 zed to improve MSC retention and therapeutic outcome.

9 hs were in the same direction as the primary outcome.

10 tify independent clinical predictors of each outcome.

11 Weight change at 18 months was a secondary outcome.

12 ed or powered to assess atrophy as a primary outcome.

13 with female fertility, measured by pregnancy outcome.

14 gene expression-based prediction of disease outcome.

15 variants on virologic response and clinical outcome.

16 ausal effect of a specific risk factor on an outcome.

17 on a variety of disease and life-expectancy outcomes.

18 and to develop new approaches to improve AKI outcomes.

19 ing to distinct anatomical and morphological outcomes.

20 a favorable effect on certain cardiovascular outcomes.

21 ution of a wide range of social and economic outcomes.

22 ing demographics, diagnoses, operations, and outcomes.

23 isoforms translate into different functional outcomes.

24 he association between volume and short-term outcomes.

25 growth and its links with later-life health outcomes.

26 th worse coronavirus disease 2019 (COVID-19) outcomes.

27 pre-eclampsia are severe, adverse pregnancy outcomes.

28 , but not FGF23, levels predicted poor renal outcomes.

29 t sensory processing and improved behavioral outcomes.

30 vity to achieve improved in vivo therapeutic outcomes.

31 tal pancreatectomy is associated with better outcomes.

32 PPV-SB were analyzed for anatomic and visual outcomes.

33 SSB) consumption is linked to adverse health outcomes.

34 otographs, and AS OCT findings were the main outcomes.

35 ad to enhancements in treatment response and outcomes.

36 effect of periodontal treatment on systemic outcomes.

37 portant factors in determining visual acuity outcomes.

38 27 associate with severe disease and adverse outcomes.

39 ows no evidence of an effect on any of these outcomes.

40 ortunity without an effect on posttransplant outcomes.

41 ationship between the observed and predicted outcomes.

42 ly in CRC and are prognostic of poor patient outcomes.

43 potential target to increase the treatment's outcomes.

44 ng nature and the severity of its associated outcomes.

45 measures and health care quality and safety outcomes.

46 apy, in which it is associated with improved outcomes.

47 cause it informs decisions to produce better outcomes.

48 an important predictor of neurodevelopmental outcomes.

49 enced higher rates and worse hospitalization outcomes.

50 e effect of ertugliflozin on HHF and related outcomes.

51 urvival (OS) and relapse free survival (RFS) outcomes.

52 end points included angiographic and safety outcomes.

53 ternal mental health in relation to specific outcomes.

54 s highly correlated with behavioral learning outcomes.

55 experiences and offspring health and disease outcomes.

56 egnancies at 41 weeks will improve perinatal outcomes.

57 n be adapted to achieve different regulatory outcomes.

58 distance was associated with lung transplant outcomes.

59 cells) than monoinfected ones with the same outcome (177 +/- 160 cells; P = .004), while survivors h

60 zed Approach was established for the primary outcome 3-month cumulative SSTI: 23 of 212 (10.8%) parti

61 most important denominator of postoperative outcome after colorectal surgery.

62 Long-term cognitive decline is an adverse outcome after major surgery associated with increased ri

63 This observational study did not show better outcomes after a second IVIg course in GBS with poor pro

64 Persistent smoking may cause adverse outcomes among patients with cancer.

65 in this review was to investigate treatment outcomes among PWID and patients on OST in comparison to

66 loading strategy (ILS) before PCI impacts on outcomes among these patients in contemporary practice r

67 Outcome analysis included tumor control, preservation of

68 nd <=90 days of follow-up were excluded from outcomes analysis.

69 multivariable model predicts the risk for an outcome and is applied to disaggregate patients within R

70 ain were detected at low rates, and cosmetic outcome and patient satisfaction with breast appearance

71 e can be applied to rapidly improve clinical outcome and reduce the risk of toxicity.

72 of APOE genotype as a biomarker for melanoma outcome and therapeutic response.

73 used to assess risk of bias for the glycemic outcome and to prepare a summary of findings table.

74 Demographic data, postoperative outcomes and complications, graft and patient survival,

75 Our models accurately predict these outcomes and identify particular prior nonopioid prescri

76 t of finerenone on individual cardiovascular outcomes and in patients with and without history of ath

77 cellular activity drive the cell to certain outcomes and phenotypes.

78 volume hospitals had less variability across outcomes and risk categories.

79 learning allows organisms to predict future outcomes and to update their beliefs about value in the

80 riables, baseline cluster-level score of the outcome, and sociodemographic characteristics.

81 s intraocular lens (IOL), visual acuity (VA) outcome, and the need for surgery for visual axis opacif

82 was to systematically evaluate the efficacy, outcomes, and complications of gamma knife radiosurgery

83 Post-transplant positive outcomes are associated with a steady reduction of right

84 Despite numerous clinical studies, outcomes are consistently disappointing with 5-year over

85 Long-term outcomes are generally good; however, the risk of compli

86 t any combinations of events predicting poor outcome as defined by a cumulative CCI >=37.1 at 90-days

87 patients had similar imaging utilization and outcomes as compared to their counterparts.

88 strongly associated with worse postoperative outcomes, as well as suicide risk.

89 In the COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therap

90 al neuroimaging, and functional neuroimaging outcomes associated with cannabis and NTP co-use.

91 Globally, the risk of severe outcomes associated with COVID-19 has consistently been

92 ars, there were no measurable differences in outcomes between patients treated with polymer-free vers

93 There were no differences in outcomes between standard dose of epinephrine and vasopr

94 erious impact on multiple sclerosis clinical outcomes but it is unclear whether this is mediated by a

95 Patient trajectories and outcomes, categorized by using the World Health Organiza

96 sical, and Overall Health) and four Specific Outcomes (Child Health-Related Quality of Life, Pain, Su

97 onhuman primates had similar overall disease outcomes compared with untreated control nonhuman primat

98 pecified secondary outcomes included primary outcome components, biological and pharmacokinetic measu

99 nse (SCR) and declarative memory of stimulus-outcome contingencies during a differential pavlovian th

100 be adaptive for efficient learning of action-outcome contingencies, above and beyond fostering person

101 The study documents the end-of-treatment outcomes, culture-conversion rates, and serious adverse

102 Pregnancy outcome data are inconsistently captured in pharmacovigi

103 Outcome data from procalcitonin-guided therapy trials ha

104 and examination of only patients with 1-year outcome data.

105 embled general surgery; however, orthopedics outcomes did not show significant differences in mortali

106 ates were 61% and 85% respectively, with ten outcomes emerging with consensus.

107 ng data were counted as having had a primary outcome event in the LMA group and as not having had suc

108 ), with 52 (6%) versus 27 (15%) experiencing outcome events during follow-up, respectively.

109 rack global reward state as well as specific outcome events.

110 o patient population, clinical settings, and outcomes examined.

111 ns between PA consistency and neurocognitive outcomes (expected mean, 50; standard deviation [SD], 10

112 e met in order to be considered a successful outcome: first, a person who initiates PrEP must not ser

113 12, we aimed to confirm results on long-term outcome focusing on efficacy and safety of long-term use

114 new tools for collection of patient-centered outcomes following catheter ablation.

115 data demonstrate the diversity of potential outcomes following Env375 modification in SHIVs.

116 We studied outcomes following living donor liver transplantation (L

117 yroid cancers and in patients who had poorer outcomes following RAI treatment.

118 stically significant improvements in patient outcomes for 26 first line therapy trials).

119 udy demonstrates ER has comparable long-term outcomes for clinical T1aN0 and T1bN0 esophageal adenoca

120 Disparities in traumatic brain injury outcomes for ethnic minorities and the uninsured have pr

121 Kidney transplant (KT) outcomes for HIV-infected (HIV+) persons are excellent,

122 ing role and a major contributor to positive outcomes for service users.

123 vices in the preoperative setting to improve outcomes for this vulnerable population.

124 Despite worse outcomes for women with AAA, no studies have prospective

125 The potential-outcomes framework characteristically requires a well-de

126 Prediction of educational outcomes from polygenic scores were inferior to those fr

127 ulation studies, the analyses of PET-imaging outcomes from the Alzheimer's Disease Neuroimaging Initi

128 This outcome has important implications for risk assessment a

129 Its incidence and outcome in critically ill patients remain, however, larg

130 e progenitor niche to determine regenerative outcome in fibrosis.

131 tudy was to characterize FUSIN drug delivery outcome in mice with regard to its dependency on several

132 iction of poor outcome, notably radiographic outcome in patients with psoriatic arthritis, so that st

133 sification during R-CHOP-14 does not improve outcome in patients with untreated DLBCL.

134 ere high with either no difference or better outcome in the 40-Gy cohort compared with the 50-Gy coho

135 Screening outcome in the era of SFM (1997-2008), the transition pe

136 ome-wide effects of free testosterone on 461 outcomes in 161,268 males from the UK Biobank study.

137 and non-fatal heart failure events and renal outcomes in all randomly assigned patients with HFrEF an

138 at FR PBM improves functional and structural outcomes in animal models of retinal injury and retinal

139 otypic differences in recurrence and patient outcomes in cervical and head and neck cancers.

140 s the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate f

141 e positive pressure ventilation (NIPPV) with outcomes in chronic obstructive pulmonary disease (COPD)

142 Obesity may contribute to adverse outcomes in coronavirus disease 2019 (COVID-19).

143 EGCG improved some cognitive and behavioral outcomes in DS mouse models and in humans with Ts21.

144 We have investigated cellular and behavioral outcomes in genetically engineered human APOE targeted r

145 fibrosis is a major determinant of clinical outcomes in heart failure (HF) patients.

146 mere maintenance mechanism (TMM) on clinical outcomes in high-risk neuroblastoma, we integrated the C

147 limit susceptibility and improve infectious outcomes in neonatal sepsis.

148 We compared outcomes in patients who received hydroxychloroquine wit

149 ation between diastolic dysfunction (DD) and outcomes in patients with aortic stenosis undergoing tra

150 ic cardiac dysfunction and impaired clinical outcomes in patients with nonischemic heart disease.

151 Identification and outcomes in patients with sepsis have improved over the

152 dy established in 2006 to evaluate perinatal outcomes in pregnant women exposed to omalizumab and the

153 F, and multifocal IOLs may provide excellent outcomes in selected cases that meet certain corneal top

154 nges were associated with long-term clinical outcomes in the COAPT population.

155 ine if tricuspid valve intervention improves outcomes in this high-risk group.

156 ditional binary outcomes, the use of ordinal outcomes in trials of cirrhosis decompensation may provi

157 have previously been demonstrated; however, outcomes in undocumented immigrants have not been examin

158 The primary outcome, in-hospital mortality, was analyzed using a mul

159 Secondary outcomes included agreement to the genotype-guided recom

160 Additional outcomes included any neuropsychiatric, anxiety, depress

161 Secondary outcomes included corrected distance visual acuity, comp

162 The primary outcomes included pathogenic variant detection performan

163 Secondary outcomes included peri-intubation complications, apneic

164 Prespecified secondary outcomes included primary outcome components, biological

165 tcome of the study was safety, and secondary outcomes included visual acuity, microperimetry and cent

166 Secondary outcomes including the score on the Owestry Disability I

167 Follow-up is ongoing for long-term outcomes, including efficacy and long-term safety.

168 Long-term outcomes, including overall survival (OS), recurrence-fr

169 n subgroups at high risk for adverse imaging outcomes, including young women and children.

170 site were significantly associated with both outcomes (increased probing depth and bone loss).

171 nagement data (including complications), and outcomes (IOP and VA) were entered in a secure online da

172 The range of possible outcomes is sufficiently wide, however, to even include

173 and recommended phase 2 dose (RP2D, primary outcome) is the FDA/EMEA approved dose of gemcitabine-na

174 to construct and validate a patient-reported outcome measure for screening and monitoring vision-rela

175 The primary outcome measure was a comparison of the DISCERN and HONc

176 The primary outcome measure was freedom from distant metastases, des

177 The primary outcome measure was HR.

178 Primary outcome measure was patient utilization of outpatient op

179 , and the optimisation was based on a single outcome measure, therefore this study should be used to

180 ular surface severity scores was the primary outcome measure, while change in CDVA was the secondary

181 sure, while change in CDVA was the secondary outcome measure.

182 Main outcomes measured were visual acuity, endothelial cell c

183 ieve harmonization of registry-based quality outcome measures for TEVAR.

184 olled in the SubPopulations and InteRmediate Outcome Measures In COPD (SPIROMICS) bronchoscopy sub-st

185 ach for establishing benchmarks for relevant outcome measures in surgery.

186 Main outcome measures were change in visual acuity and the pr

187 Primary outcome measures were changes in perimetric mean deviati

188 The primary outcome measures were confounding factors affecting the

189 Outcome measures were: (i) Intestinal and renal histopat

190 al cord blood and, as part of their clinical outcome measures, were imaged with diffusion MRI before

191 acuity, complications, and patient-reported outcomes measures.

192 Outcome metrics for living donors include patient surviv

193 One of these areas is the prediction of poor outcome, notably radiographic outcome in patients with p

194 lic volume change) and sex and the composite outcome of all-cause mortality, LV assist device implant

195 We examined the outcome of anti-tumor necrosis factor and anti-interleuk

196 primary endpoints were risk of the composite outcome of blood transfusion or death, and number of blo

197 Syndromes) trial (NCT02061891) evaluated the outcome of patients with confirmed NSTEACS randomized 1:

198 and 91% [84%, 99%] specificity in predicting outcome of SARS-CoV-2 pneumonia.

199 metastable multi-droplet state is a dynamic outcome of the interplay between two competing processes

200 data are available on its management and the outcome of the most severe forms requiring ICU admission

201 The primary outcome of the study was safety, and secondary outcomes

202 The primary outcome of this study was to determine the frequency of

203 llergen immunotherapy predicted the clinical outcome of this treatment.

204 genetics can impact progression and survival outcomes of a future malignancy and warrant prospective

205 epidemiology, clinical features, course, and outcomes of AFM to help to guide diagnosis, management,

206 een described between procedural success and outcomes of all major cardiovascular procedures.

207 t regional disparities in the management and outcomes of AMI-CS.

208 The excellent immunotherapy-independent outcomes of autoantibody-positive patients without encep

209 representations impacts the performance and outcomes of chemical machine learning methods.

210 This study evaluates outcomes of comparable pseudophakic rhegmatogenous retin

211 These unconventional outcomes of genotyping arrays include polygenic score, r

212 We aimed to analyze the outcomes of interhospital transfer (IHT) patients after

213 n these disease entities, detailed long-term outcomes of large NAFLD-associated HCC cohorts are lacki

214 Interestingly, prognostic outcomes of many cancer types have been linked with the

215 Comparing outcomes of MMCR vs ELR in patients with severe ptosis,

216 acquired pneumonia (HAP) for can improve the outcomes of patients in intensive care units (ICUs).

217 Improvements in the outcomes of patients with pancreatic ductal adenocarcino

218 study was designed to detect improvement in outcomes of patients with stage II to IV DAWT compared w

219 This study compared early and long-term outcomes of PCI versus CABG in patients with diabetes.

220 udy evaluates both functional and anatomical outcomes of retinal detachment (RD) repair by vitrectomy

221 earch is to design catalysts that select the outcomes of the reactions of complex molecules.

222 The coprimary outcomes of the trial were efficacy, as measured by the

223 de an overview of the current techniques and outcomes of transthoracic RAMIE worldwide.

224 linical characteristics and adverse clinical outcomes of U.S. invasive Hia cases detected through mul

225 matopoiesis is made possible by the emergent outcomes of vast, interconnected regulatory networks tha

226 One of the direct outcomes on the first synthesis of a complete set of cat

227 For the secondary outcomes, only the men's UBL intervention significantly

228 there were no differences in immediate event outcomes or intra-arrest hemodynamics.

229 sychopathology and individual differences in outcome over time.

230 ures were evident in patients with favorable outcomes; patients with BSP and unfavorable outcomes sho

231 The rate of the primary outcome (per 100 person-years) increased with HF duratio

232 eatment rates rather than retinal structural outcomes predictive of long-term vision.

233 We evaluated post-LT outcomes, predictors of down-staging, and the impact of

234 from each of these lineages and examined for outcomes previously found to be altered by Pb, PS, or co

235 These outcomes provide insights into the neural mechanisms und

236 intergroup learning should rely on observing outcomes, rather than actions.

237 enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 inhibitors in Subjects With

238 Patterns for vascular surgery outcomes resembled general surgery; however, orthopedics

239 ified Rankin Scale score of 0-2 or a Glasgow Outcome Scale score of 4-5.

240 essed at 6 months post injury on the Glasgow Outcome Scale-Extended (GOSE), the Short Form-12v2 and a

241 combined) results, consensus was defined as outcomes scoring greater than 90% "critical" and less th

242 Improving Pediatric Sepsis Outcomes Sepsis was defined by electronic health record

243 nt" and were included in the final PICU core outcome set: four Global Domains (Cognitive, Emotional,

244 of time in education for women and the three outcomes: sexual activity, demand for contraception, and

245 l atlases and integrating them with clinical outcomes should help identify novel predictive biomarker

246 outcomes; patients with BSP and unfavorable outcomes showed either no features, transient burst feat

247 on, effectively representing multiple future outcomes simultaneously and in parallel.

248 ully established risk prediction schemes and outcome studies using a prediction scheme for treatment

249 129 outcomes which were mapped to 43 unique outcome terms for the Delphi survey.

250 charge and survive with favorable neurologic outcomes than patients with pulseless arrests, although

251 ment function modulates SARS-CoV-2 infection outcome, the data point to putative transcriptional gene

252 Compared to traditional binary outcomes, the use of ordinal outcomes in trials of cirrh

253 results of the prespecified renal composite outcome (time to first occurrence of either: >=50% reduc

254 y between brain regions predict differential outcome to antidepressant medication (sertraline) compar

255 lth technology could enable patient-reported outcomes to inform appropriate timing of face-to-face vi

256 pre-intervention achievement against primary outcomes, total quality scores, and levels of patient co

257 n and its use is supported by large clinical outcome trials.

258 the findings of the completed cardiovascular outcome trials.

259 to total energy intake and adverse pregnancy outcomes using targeted maximum likelihood estimation (T

260 Clinical outcomes vary among youths at clinical high risk for psy

261 Visual acuity outcomes vary; however, patients can recover excellent v

262 95% CI 25% to 30%) and favourable functional outcome was 45% (95% CI 40% to 50%) and after haematoma

263 The primary outcome was all-cause mortality, and the secondary outco

264 e was all-cause mortality, and the secondary outcome was cause-specific mortality.

265 Primary outcome was COPD defined by postbronchodilator ratio of

266 The primary outcome was death or colectomy within 90 days after the

267 Favourable functional outcome was defined as a modified Rankin Scale score of

268 The primary outcome was disability, measured with the Expanded Disab

269 The primary outcome was failure to spontaneously pass the gestationa

270 The primary outcome was long-term survival.

271 Primary outcome was overall response rate.

272 The primary outcome was reperfusion of greater than 50% of the invol

273 to 2012 with follow-up through 2014, and the outcome was surgical reintervention.

274 The primary outcome was the proportion of adolescents who had died o

275 The primary outcome was the rate of decline in the total score on th

276 rcutaneous coronary intervention.The primary outcome was the rate of prasugrel or ticagrelor prescrib

277 The primary outcome was the severity of lung disease on admission ch

278 The primary outcome was time to death or symptomatic stroke confirme

279 Primary outcome was time to functional recovery and length of ho

280 The primary outcome was time-weighted average of hypotension during

281 ematic collation of certain important safety outcomes was rare.

282 To improve therapeutic outcomes, we microinjected ASO directly into the E12.5 i

283 Absolute 10-year risks of outcomes were as follows: HF: 3.18% (95% confidence inte

284 Outcomes were assessed according to patients' receipt of

285 Precancerous outcomes were compared between unvaccinated and HPV-vacc

286 Ninety-day outcomes were evaluated by blinded telephone interviewer

287 rsus 4.1%, OR, 6.49; P<0.001), and composite outcomes were higher for both inconclusive tests (stress

288 The primary outcomes were in-hospital vascular complications and ble

289 Outcomes were measured by the clinical composite score (

290 The most investigated outcomes were periodontal diseases (42%) and oral cancer

291 n follow-up of 4.8 years (range, 1-7 years), outcomes were resolution of exudation or proliferation w

292 V-SB compared with PPV alone, whereas visual outcomes were similar for both groups.

293 Secondary outcomes were the percentage of cases associated with sp

294 The primary outcomes were the proportion of participants with major

295 Main outcomes were treatment failure (the proportion of women

296 e generalized linear mixed models for binary outcomes were used to examine the relationship between d

297 B-cell acute lymphocytic leukaemia have poor outcomes when treated with regimens that do not contain

298 The systematic review identified 129 outcomes which were mapped to 43 unique outcome terms fo

299 and there have been no subsequent reports of outcomes with this technique.

300 r normally to measure pregnancy and neonatal outcomes, with a subset sacrificed at E19.5 for placenta